We present a case of high-grade serous carcinoma of Mullerian primary with a novel FGFR2::IQCG fusion an exceedingly rare combination of tumor type and fusion class, which progressed through multiple lines of therapy before and after a brief period on futibatinib. Here, FGFR2 is linked to neoplasm.